How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

819 results for

Galantamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

781. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. (Full text)

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. To provide an update review of the best quality evidence for the clinical effectiveness and cost-effectiveness of donepezil, rivastigmine and galantamine for mild to moderately severe Alzheimer's disease (AD) and of memantine for moderately severe to severe AD.Electronic databases, experts in the field and manufacturer submissions to the National Institute for Health and Clinical (...) -analysis of data was undertaken.For mild to moderately severe AD, the results of the study suggested that all three treatments were beneficial when assessed using cognitive outcome measures. Global outcome measures were positive for donepezil and rivastigmine, but mixed for galantamine. Results for measures of function were mixed for donepezil and rivastigmine, but positive for galantamine. Behaviour and mood measures were mixed for donepezil and galantamine, but showed no benefit for rivastigmine

2006 Health technology assessment (Winchester, England) PubMed abstract

782. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. (Full text)

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Pharmacologic treatments for Alzheimer's disease include the cholinesterase inhibitors donepezil, galantamine, and rivastigmine. We reviewed their evidence by searching MEDLINE, Embase, The Cochrane Library, and the International Pharmaceutical Abstracts from 1980 through 2007 (July) for placebo-controlled and comparative trials assessing cognition (...) , function, behavior, global change, and safety. Thirty-three articles on 26 studies were included in the review. Meta-analyses of placebo-controlled data support the drugs' modest overall benefits for stabilizing or slowing decline in cognition, function, behavior, and clinical global change. Three open-label trials and one double-blind randomized trial directly compared donepezil with galantamine and rivastigmine. Results are conflicting; two studies suggest no differences in efficacy between compared

2008 Clinical interventions in aging PubMed abstract

783. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. (Full text)

A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. The use of cholinesterase inhibitors for Alzheimer's disease (AD) is currently being appraised by the National Institute for Clinical Evidence (NICE). This article provides the latest evidence that NICE will be using as part of this appraisal process.To provide a systematic review of the best quality evidence of the effects (...) of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in people with mild to moderately-severe AD.Electronic databases were searched, references of all retrieved articles were checked, and experts were contacted for advice, peer review and to identify additional references. Randomised controlled trials (RCTs) were included if they fulfilled pre-specified criteria. Data were synthesised through a narrative review.Twenty-six RCTs that compared any one

2006 International Journal of Geriatric Psychiatry PubMed abstract

784. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. (Abstract)

Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. The authors estimated the effects of each of the three commonly used drugs for Alzheimer disease (donepezil, galantamine, and rivastigmine) in terms of predefined clinical outcomes and trial completion rates, by dosing level, and described differences among them. Using both electronic and manual search strategies (January 1992 to July 2002 (...) ), a metaanalysis examined the effect of the drugs on clinical outcomes and completion rates. Regression analyses compared the effect of dose on clinical outcomes and completion rates, using 10 donepezil, 6 galantamine, and 5 rivastigmine articles. All three drugs showed beneficial effects on cognitive tests, as compared with placebo. For donepezil and rivastigmine, larger doses were associated with larger effect. This was not the case with galantamine. The odds of clinical global improvement demonstrated

2004 The American Journal of Geriatric Psychiatry

785. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis. (Full text)

A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis. This review was conducted in order to determine the efficacy of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease, and also to determine whether galantamine was a superior pharmacological intervention. Meta-analytic methods were used to analyse the data from eight empirical studies which met the inclusion criteria specified. By finding (...) the mean effect sizes of the treatment on the outcome measures of cognition, it was determined that neither drug was greatly efficacious. However, this result does not necessarily diminish the practical value of the drug. It was also found that galantamine was no better than donepezil at treating cognitive decline in AD.Copyright (c) 2005 John Wiley & Sons, Ltd.

2005 Human psychopharmacology PubMed abstract

786. Galantamine for vascular cognitive impairment. (Abstract)

Galantamine for vascular cognitive impairment. Vascular dementia is the second most common form of dementia. Cholinesterase inhibitors modestly improve a broad range of symptoms in some patients with Alzheimer's disease through enhancement of cholinergic neurotransmission. These drugs may also be beneficial in vascular dementia as reductions in acetylcholine and acetyltransferase activity have been reported.To assess the efficacy of galantamine in the treatment of people with vascular cognitive (...) impairment or vascular dementia or "mixed" dementia.Trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 19 April 2005 using the terms: galantamine. galanthamine, reminyl. All major health care databases and many ongoing trial databases within the scope of the group are searched regularly to keep this Register up to date.All unconfounded randomised double-blind trials comparing galantamine with placebo were eligible for inclusion.Two

2006 Cochrane database of systematic reviews (Online)

787. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. (Abstract)

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Vascular dementia is the second commonest form of dementia, and vascular factors contribute to the development of dementia in many patients with Alzheimer's disease. Galantamine amplifies the acetylcholine response by inhibiting acetylcholinesterase and modulating nicotinic receptors. It has shown broad, sustained benefits in patients with Alzheimer's disease (...) . We investigated the effects of galantamine in patients with a diagnosis of probable vascular dementia or Alzheimer's disease combined with cerebrovascular disease.Eligible patients were randomly assigned galantamine 24 mg/day (n=396) or placebo (n=196) in a multicentre, double-blind, 6-month trial. Primary endpoints were cognition (Alzheimer's disease assessment scale, cognitive subscale [ADAS-cog]) and global functioning (clinician's interview-based impression of change plus caregiver input

2002 Lancet Controlled trial quality: predicted high

788. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. (Abstract)

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. 12169216 2002 11 15 2013 11 21 1528-4042 2 5 2002 Sep Current neurology and neuroscience reports Curr Neurol Neurosci Rep Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. 389-90 Marder Karen K eng Clinical Trial Editorial Multicenter Study Randomized Controlled Trial United (...) States Curr Neurol Neurosci Rep 100931790 1528-4042 0 Cholinesterase Inhibitors 0D3Q044KCA Galantamine IM Alzheimer Disease complications drug therapy Cerebrovascular Disorders complications Cholinesterase Inhibitors pharmacology therapeutic use Cognition drug effects physiology Dementia, Vascular complications drug therapy Double-Blind Method Galantamine pharmacology therapeutic use Humans Treatment Outcome 2002 8 10 10 0 2002 11 26 4 0 2002 8 10 10 0 ppublish 12169216

2002 Current neurology and neuroscience reports Controlled trial quality: uncertain

789. Galantamine may be effective in treating autistic disorder. (Abstract)

Galantamine may be effective in treating autistic disorder. 12480867 2003 01 10 2018 11 13 1756-1833 325 7377 2002 Dec 14 BMJ (Clinical research ed.) BMJ Galantamine may be effective in treating autistic disorder. 1422 Niederhofer Helmut H Staffen W W Mair A A eng Clinical Trial Comment Letter Randomized Controlled Trial England BMJ 8900488 0959-8138 0 Nootropic Agents 0D3Q044KCA Galantamine AIM IM BMJ. 2000 Dec 9;321(7274):1445-9 11110737 Autistic Disorder drug therapy Child Cross-Over Studies (...) Double-Blind Method Galantamine therapeutic use Humans Male Nootropic Agents therapeutic use Treatment Outcome 2002 12 14 4 0 2003 1 11 4 0 2002 12 14 4 0 ppublish 12480867 PMC1124870 BMJ. 2000 Dec 9;321(7274):1445-9 11110737 J Autism Child Schizophr. 1972 Oct-Dec;2(4):343-58 4581614 Psychopharmacol Bull. 1988;24(2):251-5 3212157 Am J Ment Defic. 1985 Mar;89(5):492-502 3158201 J Am Acad Child Adolesc Psychiatry. 1988 Mar;27(2):248-51 3360732

2003 BMJ (Clinical research ed.) Controlled trial quality: uncertain

790. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. (Abstract)

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. 12359103 2003 01 13 2013 11 21 1528-4042 2 6 2002 Nov Current neurology and neuroscience reports Curr Neurol Neurosci Rep Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. 503-4 Kertesz Andrew A eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial (...) United States Curr Neurol Neurosci Rep 100931790 1528-4042 0 Cholinesterase Inhibitors 0D3Q044KCA Galantamine IM Alzheimer Disease complications drug therapy Cerebrovascular Disorders complications Cholinesterase Inhibitors adverse effects therapeutic use Dementia, Vascular complications drug therapy Double-Blind Method Galantamine adverse effects therapeutic use Humans Nausea chemically induced Psychiatric Status Rating Scales Severity of Illness Index Treatment Outcome Vomiting chemically induced

2003 Current neurology and neuroscience reports Controlled trial quality: uncertain

791. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice (Full text)

Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice Phenotypic knockout of nerve growth factor (NGF) activity in transgenic anti-NGF mice (AD11 mice) results in a progressive neurodegenerative phenotype resembling Alzheimer's disease. In this article, we examine whether and how the progressive neurodegenerative phenotype of AD11 mice could be prevented or ameliorated by pharmacological treatments with NGF or the cholinergic agonist (...) galantamine, at a relatively early phase of Alzheimer's disease-like neurodegeneration. We demonstrate that the neurodegeneration induced by the expression of anti-NGF antibodies in AD11 mice can be largely reversed by NGF delivery through an olfactory route.

2002 Proceedings of the National Academy of Sciences of the United States of America PubMed abstract

792. Evaluation of Galantamine in the Treatment of Alzheimer's Disease

Evaluation of Galantamine in the Treatment of Alzheimer's Disease Evaluation of Galantamine in the Treatment of Alzheimer's Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Evaluation of Galantamine (...) to Brief Summary: Galantamine is an experimental drug being evaluated in the United States for the treatment of Alzheimer's disease. Results from previous clinical trials suggest that galantamine may improve cognitive performance in individuals with Alzheimer's disease. It is not a cure for Alzheimer's disease. Nerve cells in the brain responsible for memory and cognitive function communicate using a chemical called acetylcholine. Research has shown that deterioration of cells that produce

1999 Clinical Trials

793. A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia

A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00035191 Recruitment Status : Completed First Posted : May 3

2002 Clinical Trials

794. A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease

A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov

2002 Clinical Trials

795. Galantamine: additional benefits to patients with Alzheimer's disease. (Abstract)

Galantamine: additional benefits to patients with Alzheimer's disease. Galantamine, a novel treatment for Alzheimer's disease (AD), has a dual mechanism of action, combining allosteric modulation of nicotinic acetylcholine receptors with reversible, competitive inhibition of acetylcholinesterase. In the Phase III clinical trial programme, over 3,000 patients with mild-to-moderate AD were enrolled in one of five randomized, controlled, double-blind studies. Using the Alzheimer's Disease (...) Assessment Scale-cognitive subscale (ADAS-cog) to assess memory and other cognitive functions, galantamine was found to be significantly superior to placebo in all five studies at doses of 16, 24 and 32 mg/day. In all studies, galantamine-treated patients maintained their cognitive function, whereas the placebo-treated patients experienced a significant deterioration in ADAS-cog scores. The 32-mg/day dose was not associated with any additional cognitive benefit. Pooled data from two 6-month studies (n

2000 Dementia and Geriatric Cognitive Disorders

796. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. (Abstract)

Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Despite the proven efficacy of acetylcholinesterase inhibitors in Alzheimer's disease, there is a need for new and more effective treatments. Galantamine is a novel treatment for Alzheimer's disease that inhibits acetylcholinesterase and modulates nicotinic receptors. In randomized, double-blind, placebo-controlled studies of up to 6 months duration (...) , galantamine significantly improved cognitive function. Galantamine also had beneficial effects on instrumental and basic activities of daily living, and postponed the progression of behavioral symptoms. Patients who completed one of the 6-month, placebo-controlled studies were eligible to enter a 6-month, open-extension study of the 24-mg/day dose of galantamine. At the end of 12 months, cognitive function and activities of daily living were preserved in those patients who had been treated throughout

2001 Biological psychiatry

797. Galantamine slows functional decline in Alzheimer's disease (Full text)

Galantamine slows functional decline in Alzheimer's disease 11110753 2000 12 23 1756-1833 321 7274 2000 Dec 09 BMJ (Clinical research ed.) BMJ Galantamine slows functional decline in Alzheimer's disease D eng Journal Article England BMJ 8900488 0959-8138 2000 12 9 2000 12 9 2000 12 9 0 0 ppublish 11110753 PMC1119149

2000 BMJ : British Medical Journal PubMed abstract

798. The effects of galantamine treatment on caregiver time in Alzheimer's disease. (Full text)

The effects of galantamine treatment on caregiver time in Alzheimer's disease. The aim of the study was to determine whether the clinical benefits of galantamine for patients with Alzheimer's disease lead to benefits for caregivers.Data were pooled from two concurrent, multi-centre, randomized, double-blind, placebo-controlled, 6-month trials. Time caregivers spent assisting with activities of daily living (ADL) and time patients could be left unsupervised each day were assessed using (...) the Allocation of Caregiver Time Survey. In total, 825 patients with mild-to-moderate Alzheimer's disease were included.At endpoint, caregivers of galantamine-treated patients were more likely to report reductions (41% vs 37%), maintenance (19% vs 14%) or smaller increases (26% vs 34% reporting an increase >30 minutes) in time assisting with ADL compared with the placebo group (p=0.026; Wilcoxon rank-sum test). The mean daily time difference was 32 minutes (p=0.011). Among patients with moderate Alzheimer's

2003 International Journal of Geriatric Psychiatry Controlled trial quality: predicted high PubMed abstract

799. The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure. (Full text)

The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure. Acetylcholinesterase inhibitors (AChEIs) can provide benefits at the cognitive, behavioral, and functional levels to patients with Alzheimer's disease (AD). With more AChEIs now available, treatment considerations may include whether the patient has had prior exposure to an AChEI.To compare the effects (...) of galantamine in patients with AD who were previously exposed to AChEIs with its effects in patients with AD who had no previous exposure, using a post hoc analysis.Patients in groups treated with galantamine 16 mg/day and 24 mg/day achieved statistically significant improvements in ADAS-cog/11 scores in comparison with those who received placebo (naive: p = 0.003 and 0.005, respectively; prior exposure: p < 0.001 and 0.001, respectively). Similarly, a greater number of patients treated with galantamine 16

2003 International Journal of Geriatric Psychiatry Controlled trial quality: uncertain PubMed abstract

800. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. (Abstract)

A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. To compare the long-term efficacy and safety of galantamine 24 mg/day and donepezil 10 mg/day in patients with Alzheimer's disease.This was a rater-blinded, randomised, parallel-group multicentre study (18 outpatient clinics) in the UK. 182 patients (69 male, 113 female) with Alzheimer's disease were randomised to galantamine (n = 94) or donepezil (n = 88) for 52 weeks.The effects of galantamine (...) of cognition, galantamine patients' scores on the MMSE at week 52 did not differ significantly from baseline (-0.52 +/- 0.39, p < 0.5 vs baseline), whereas donepezil patients' scores deteriorated significantly from baseline (-1.58 +/- 0.42, p < 0.0005 vs baseline). The between-group difference in MMSE change, which showed a trend for superiority of galantamine, did not reach statistical significance (p < or = 0.1). In the ADAS-cog/11 analysis, between-group differences for the total population were

2003 Drugs & Aging Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>